Uncategorized
FDA accepts NDA for Rhopressa
The FDA has accepted a new drug application for Rhopressa and set a PDUFA goal date of Feb. 28, 2018, according to a press release from Aerie Pharmaceuticals.Rhopressa (netarsudil ophthalmic solution 0.02%) is a once-daily eye drop designed to lower IOP by targeting the trabecular meshwork.